Literature DB >> 10366577

Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits.

D Shang1, W Zhai, J P Allain.   

Abstract

The HCV hypervariable region 1 (HVR1) of the main E2 envelope protein is critically important in HCV neutralization but its extreme variability makes immune therapy and vaccine development particularly difficult. To explore the hypothesis that HVR1 carries a common epitope susceptible of eliciting cross-reactive neutralizing and inhibitory antibodies, rabbits were immunized with a series of synthetic HVR1 peptides. The anti-HVR1 produced were purified and characterized. Several lines of evidence supported the working hypothesis: (1) although injected only once, a boosting effect from poorly homologous peptides was observed; (2) purified rabbit IgG reacted with high affinity with immunizing peptides and cross-reacted with 16 of 17 unrelated HVR1 peptides; (3) antibodies appeared of restricted diversity irrespective of the linear HVR1 peptide sequences; (4) anti-HVR1 peptides effectively captured HCV in 22 of 33 plasmas from random infected patients; (5) anti-HVR1 IgG blocked the binding of antibody-captured HCV to MOLT-4 cells. These findings suggest that with an appropriate HVR1 peptide immunization scheme, high titer, broadly cross-reactive, blocking antibodies to HCV can be produced. Antibodies to the putative ubiquitous HVR1 epitope may have important clinical uses. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366577     DOI: 10.1006/viro.1999.9730

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.

Authors:  T A Pitcovsky; J Mucci; P Alvarez; M S Leguizamón; O Burrone; P M Alzari; O Campetella
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1.

Authors:  C Li; D Candotti; J P Allain
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.

Authors:  Jing Jin; Jian-Ying Yang; Jing Liu; Yu-Ying Kong; Yuan Wang; Guang-Di Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

4.  Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.

Authors:  Alexander W Tarr; Richard A Urbanowicz; Mohamed R Hamed; Anna Albecka; C Patrick McClure; Richard J P Brown; William L Irving; Jean Dubuisson; Jonathan K Ball
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

Review 5.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

6.  Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus.

Authors:  Bing-Shui Xiu; Shi-Gan Ling; Xiao-Guo Song; He-Qiu Zhang; Kun Chen; Cui-Xia Zhu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 7.  Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein.

Authors:  Faezeh Ghasemi; Majid Ghayour-Mobarhan; Hamed Gouklani; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2018-07-17

8.  A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice.

Authors:  Reham M Dawood; Rehab I Moustafa; Tawfeek H Abdelhafez; Reem El-Shenawy; Yasmine El-Abd; Noha G Bader El Din; Jean Dubuisson; Mostafa K El Awady
Journal:  BMC Infect Dis       Date:  2019-11-05       Impact factor: 3.090

Review 9.  Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.

Authors:  Heidi E Drummer
Journal:  Front Microbiol       Date:  2014-07-03       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.